Less Ads, More Data, More Tools Register for FREE

Pin to quick picksORPH.L Regulatory News (ORPH)

  • There is currently no data for ORPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

6 Jan 2021 16:29

RNS Number : 8284K
Open Orphan PLC
06 January 2021
 

Standard Form TR-1

Standard form for notification of major holdings

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the Central Bank of Ireland)i

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Open Orphan PLC GB00B9275X97

LEI 213800VT5KBM7JLIV118

2. Reason for the notification (please tick the appropriate box or boxes):

[X] An acquisition or disposal of voting rights

[ ] An acquisition or disposal of financial instruments

[ ] An event changing the breakdown of voting rights

[ ] Other (please specify)iii:

3. Details of person subject to the notification obligationiv :

Name: Invesco Ltd.

City and country of registered office (if applicable):

1555 Peachtree Street NE, Suite 1800, Atlanta, GA 30309 United States.

4. Full name of shareholder(s) (if different from 3.)v:

 

5. Date on which the threshold was crossed or reachedvi:

04-01-2021

6. Date on which issuer notified:

06-01-2021

7. Threshold(s) that is/are crossed or reached:

5% reached

8. Total positions of person(s) subject to the notification obligation:

% of voting rights attached to shares (total of 9.A)

% of voting rights through financial instruments(total of 9.B.1 + 9.B.2)

Total of both in % (9.A + 9.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

5.96%

0%

5.96%

668,052,261

Position of previous notification (if applicable)

9.86%

0%

9.86%

 

9. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii:

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

 

Direct

 

 

Indirect

 

 

Direct

 

 

Indirect

 

GB00B9275X97

0

39,831,346

0

5.96%

SUBTOTAL A

39,831,346

5.96%

B 1: Financial Instruments according to Regulation 17(1)(a) of the Regulations

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is exercised/converted.

% of voting rights

SUBTOTAL B.1

B 2: Financial Instruments with similar economic effect according to Regulation 17(1)(b) of the Regulations

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash settlementxii

Number of voting rights

% of voting rights

SUBTOTAL B.2

 

10. Information in relation to the person subject to the notification obligation (please tick the applicable box):

 

[ ] Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.xiii

 

[X] Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv:

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Invesco Asset Management Limited

5.96%

0%

5.96%

11. In case of proxy voting: [name of the proxy holder] will cease to hold [% and number] voting rights as of [date]

 

 

12. Additional informationxvi:

Click here to enter text.

 

Done at Henley-on-Thames on 06-01-2021

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLBLGDBLDGDGBL
Date   Source Headline
25th Oct 20227:00 amRNSChange of name to hVIVO plc effective
20th Oct 20227:00 amRNSCapital Markets Day
18th Oct 20227:00 amRNSCFO appointment & change of Board roles
30th Sep 20227:00 amRNSPositive in vitro results for FLU-v published
29th Sep 20229:30 amRNSDirector dealings
27th Sep 20227:00 amRNSUpcoming Scientific Presentations
15th Sep 20227:00 amRNSComment regarding press speculation
8th Sep 20227:01 amRNSInterim results and trading update
8th Sep 20227:00 amRNSIntention to change name to hVIVO plc
1st Sep 20227:20 amRNSCAP accreditation
25th Aug 20227:00 amRNSNotice of results
22nd Aug 20227:00 amRNS£10.4m contract with existing Big Pharma client
4th Aug 20227:00 amRNS£6.2m Influenza human challenge study contract
5th Jul 20221:17 pmRNSResult of AGM
30th Jun 20227:00 amRNSOmicron human challenge model
14th Jun 20227:00 amRNS£7.2m RSV human challenge study contract
10th Jun 202212:13 pmRNSBoard appointment amendment
10th Jun 202212:00 pmRNSAnnual Report and Notice of AGM
8th Jun 20227:00 amRNSBoard appointment
7th Jun 20229:05 amRNSSecond Price Monitoring Extn
7th Jun 20229:00 amRNSPrice Monitoring Extension
7th Jun 20227:00 amRNSFinal results
1st Jun 20227:00 amRNSGBP14.7m influenza contract signed
26th May 20227:00 amRNSCompletion of Nominated Adviser due diligence
24th May 20227:00 amRNSNotice of results
18th May 20227:00 amRNS£7.3m Influenza human challenge study contract win
12th May 20227:00 amRNSWellcome publication
5th May 20227:00 amRNSVaccine field study contract
4th May 20227:00 amRNSChallenge virus manufacturing contract
4th May 20227:00 amRNSComment re: speculation
28th Apr 20227:00 amRNSAppointment of Nominated Adviser and Joint Broker
13th Apr 20227:00 amRNSProposal to Distribution in Specie Shareholders
12th Apr 202212:00 pmRNSPresentation at World Vaccine Congress
6th Apr 20224:35 pmRNSPrice Monitoring Extension
6th Apr 20222:05 pmRNSSecond Price Monitoring Extn
6th Apr 20222:01 pmRNSPrice Monitoring Extension
6th Apr 202211:05 amRNSSecond Price Monitoring Extn
6th Apr 202211:00 amRNSPrice Monitoring Extension
31st Mar 202210:05 amRNSCharacterisation Study results in Nature Medicine
25th Mar 20227:00 amRNS£5m RSV human challenge study contract win
9th Mar 20224:41 pmRNSSecond Price Monitoring Extn
9th Mar 20224:37 pmRNSPrice Monitoring Extension
8th Mar 20227:00 amRNSTrading Update and screening facilities expansion
7th Mar 20222:06 pmRNSSecond Price Monitoring Extn
7th Mar 20222:00 pmRNSPrice Monitoring Extension
7th Mar 202211:06 amRNSSecond Price Monitoring Extn
7th Mar 202211:00 amRNSPrice Monitoring Extension
2nd Mar 20227:00 amRNSInvestor Presentations
24th Feb 20227:00 amRNSCEO Appointment
22nd Feb 20227:00 amRNSFDA Breakthrough Designation for Big Pharma RSV

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.